Pfizer has announced positive topline results from a Phase II trial of its first-in-class IL-4×IL-13×TSLP trispecific antibody (TsAb), tilrekimig (PF-07275315), for moderate-to-severe atopic dermatitis. The candidate, which is the only drug of its kind in development globally, is designed for monthly administration. The study met its primary efficacy endpoint, with a significantly higher proportion of patients treated with tilrekimig achieving a 75% improvement in eczema area and severity index (EASI-75) at 16 weeks compared to placebo. The therapy was well-tolerated, with a safety profile comparable to placebo and a notably lower incidence of conjunctivitis than has been observed with IL-4Rα inhibitors.

The Phase II study will continue to evaluate tilrekimig in atopic dermatitis, while Pfizer is also advancing the candidate in Phase II trials for asthma and a Phase IIb/III trial for chronic obstructive pulmonary disease (COPD). The company plans to initiate a pivotal Phase III trial for atopic dermatitis later in 2026. The positive data support the potential of tilrekimig as a new monthly treatment option for diseases driven by type 2 inflammation.

PharmCube's NextBiopharm® database lists four active projects globally targeting IL-4 in atopic dermatitis, all multispecific antibodies. Click here to request a free trial for NextBiopharm®.